Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.
20

Bausch + Lomb Unveils AMD Virtual Experience with State-of-the-Art Technology at Optometry’s Meeting

Interactive Simulation Enables Eye Care Professionals to Experience the Effects of Age-Related Macular Degeneration (AMD) Through Their Patients’ Eyes


FOR RELEASE TUESDAY, JUNE 20, 2017

BRIDGEWATER, NJ –  Bausch + Lomb, a leading global eye health company, today announced the launch of a new virtual reality (VR) tool using state-of-the-art technology. The Age-Related Macular Degeneration (AMD) Virtual Experience, unveiled during the annual meeting of the American Optometric Association (AOA), June 21-25, in Washington, DC, will allow eye care professionals to experience the daily challenges this condition brings their patients with mild to more advanced stages of AMD. 

“We’ve developed several initiatives to raise awareness around this condition. Now, for the first time, we’ve created a platform that goes beyond traditional awareness and enables eye care professionals to see what life is like with AMD,” said Joseph Gordon, president, Consumer Health & Vision Care, Bausch + Lomb. “We are continuously looking for creative ways to educate the public about eye health and we hope by showing eye care professionals their AMD patients’ struggles first-hand, it will encourage them to be even better stewards of care.”  

AMD is a progressive eye disease, affecting an estimated 13 million people, and is a leading cause of vision loss in people age 50 and older. Approximately one out of five people over the age of 65 will be diagnosed with the disease, characterized by the loss of central vision. While there is no cure, certain steps, such as smoking cessation, regular exercise, a healthy diet and taking an AREDS 2 eye vitamin can help reduce the risk of progression. PreserVision® AREDS 2 has the exact nutrient formula recommended by the National Eye Institute for people with moderate-to-advanced AMD.

“I spend a lot of time talking to my AMD patients and their family members about steps they can take to help reduce their risk of disease progression,” said Jeffry Gerson, an optometrist from Grin Eye Care in Leawood, Kansas. “Now, after being able to fully relate to what my patients are dealing with through the AMD Virtual Experience, it has underscored, even more, the importance for me as a practitioner to communicate to my patients the importance of reducing their risk of progression.” 

AOA attendees are invited to experience the virtual reality tool by visiting the Bausch + Lomb booth (#155) at any time during the meeting. 

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Our core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries.


PreserVision is a trademark of Bausch & Lomb Incorporated or its affiliates. AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS). All other product/brand names and/or logos are trademarks of the respective owners. 
© 2017 Bausch & Lomb Incorporated.

News Media Contacts:

Kristy Marks
Director, Corporate Communications, Bausch + Lomb
(908) 927-0683 or kristy.marks@bausch.com
  
Don Murphy
Zeno Group, on behalf of Bausch + Lomb
(212) 299-8970 or don.murphy@zenogroup.com

PV2.0065.USA.17

Actions: E-mail | Permalink |